CYP2C9*3 allelic variant and bleeding complications

Lancet. 1999 Sep 25;354(9184):1124. doi: 10.1016/S0140-6736(05)76918-X.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Aryl Hydrocarbon Hydroxylases*
  • Cytochrome P-450 CYP2C9
  • Cytochrome P-450 Enzyme System / genetics*
  • Double-Blind Method
  • Genotype
  • Hemorrhage / chemically induced
  • Hemorrhage / genetics*
  • Humans
  • Male
  • Myocardial Ischemia / prevention & control
  • Steroid 16-alpha-Hydroxylase*
  • Steroid Hydroxylases / genetics*
  • Thrombosis / prevention & control
  • Warfarin / adverse effects*
  • Warfarin / metabolism

Substances

  • Warfarin
  • Cytochrome P-450 Enzyme System
  • Steroid Hydroxylases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Steroid 16-alpha-Hydroxylase